Treatment patterns of high-dose-rate and low-dose-rate brachytherapy as monotherapy for prostate cancer.
Conclusions: We observed an overall decrease in brachytherapy (BT) monotherapy use since 2004 for localized prostate cancer. Despite similar survival outcomes, the use of HDR monotherapy declined relative to LDR. PMID: 31523232 [PubMed]
Conclusions: Fluoroscopy and 3D CT image-guided interstitial brachytherapy is feasible and appears to be a suitable treatment technique for patients with clinically localized prostate cancer after previous rectal resection and external beam radiation therapy. PMID: 31435432 [PubMed]
Authors: Latorzeff I Abstract Prostate cancer is a sensitive adenocarcinoma, in more than 80 % of cases, to chemical castration, due to its hormone dependence. Locally advanced and/or high-risk cancer is defined based on clinical stage, initial PSA value or high Gleason score. Hormone therapy associated with radiation therapy is the standard of management and improves local control, reduces the risk of distant metastasis and improves specific and overall survival. Duration of hormone therapy, dose level of radiation therapy alone or associated with brachytherapy are controversial data in the literature. Radical pro...
CONCLUSIONS: Differed strategies still accounted for a small percentage of treatments. PR and RT/BT were of choice in patients with localized stages of the disease and younger than 70 years. More advanced stages and older patients were treated with HT mainly. Age is postulated as the main factor involved in therapeutic decision making. PMID: 31223124 [PubMed - in process]
Neoadjuvant hormone therapy (NHT) when given to men receiving radiation therapy (RT) for prostate cancer is known to affect long term testosterone (T) levels. Men with suppressed T may experience a lower PSA value which could influence biochemical failure determinations. We sought to determine which factors influenced the last measured T and PSA values and the relationship between the two.
Prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging has already been integrated into the routine diagnostic workup of prostate cancer in Western countries. Increased PSMA expression in prostate tissues is associated with tumor aggressiveness. However, the serum level of PSMA are usually 50- to 100-fold lower than those of PSA. Therefore, the changes in the serum level of PSMA after brachytherapy and hormonal therapy in patients are unknown. Here, we investigated the serum PSMA level in prostate cancer patients treated by brachytherapy and/or hormonal therapy.
Conclusions: This review found substantial evidence that prostate cancer indicators varied by residential location across diverse populations and geographies. While wide variations in study design limited comparisons across studies, our review indicated that internationally, men living in disadvantaged areas, and to a lesser extent more rural areas, face a greater prostate cancer burden. This review highlights the need for a better understanding of the complex social, environmental, and behavioral reasons for these variations, recognizing that, while important, geographical access is not the only issue. Implementing resear...
CONCLUSIONS: PLN-RT occurred in about one-third of men receiving external beam radiotherapy and increased over time, mostly in men with very high-risk CaP for unclear reasons. Of concern, over one-quarter of low-risk men receive PLN-RT. Further work is needed to understand the heterogeneity in PLN-RT use. We await the completion of RTO G 09-24 to better understand the role of PLN-RT for men with localized CaP. PMID: 30611643 [PubMed - as supplied by publisher]
CONCLUSION: HDR-BT monotherapy showed an equivalent outcome to that of LDR-BT with or without EBRT for low-, intermediate- and selected high-risk patients. LDR-BT showed equivalent incidence of grade ≥2 late GI and GU toxicities and higher grade ≥2 acute GU toxicity as that of HDR-BT as a monotherapy. PMID: 30416045 [PubMed - as supplied by publisher]
ConclusionsDuring follow-up consultations, little attention is paid to the impact of treatment-induced sexual dysfunction on the relationship of men with prostate cancer and their partners. A standard consultation with a urologist-sexologist 3 months after treatment to discuss sexual and relational issues is considered as most preferable.
BJU International, EarlyView.